Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 55 Cambridge Pkwy Ste 901E CAMBRIDGE MA 02142-1234 |
Tel: | N/A |
Website: | https://www.kalvista.com |
IR: | See website |
Key People | ||
Benjamin L. Palleiko Chief Executive Officer, Director | Edward P. Feener Chief Scientific Officer | Paul K. Audhya Chief Medical Officer |
Nicole Sweeny Chief Commercial Officer | Christopher M. Yea Chief Development Officer |
Business Overview |
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema. |
Financial Overview |
For the nine months ended 31 January 2024, Kalvista Pharmaceuticals Inc revenues was not reported. Net loss increased 23% to $82M. Higher net loss reflects pharmaceutical segment loss increase from $25.9M to $92M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.60 to -$2.37. |
Employees: | 118 as of Apr 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $366.97M as of Jan 31, 2024 |
Annual revenue (TTM): | $0.00M as of Jan 31, 2024 |
EBITDA (TTM): | -$122.93M as of Jan 31, 2024 |
Net annual income (TTM): | -$108.30M as of Jan 31, 2024 |
Free cash flow (TTM): | -$97.15M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 42,188,296 as of Mar 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |